Rigel Pharma (RIGL) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 --0%
EPS Growth %: -34.9%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -34.9%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.9 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- BMS myeloma CAR T therapy meets primary endpoint in phase 2 trial
- Oil near $100, Fed rate fears and Iran tensions - what’s moving markets
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
